Secondary sulphonylurea failure: what pathogenesis is responsible?

Area of Science:

• Endocrinology
• Metabolic Diseases
• Diabetes Research

Background:

• Sulphonylurea (SU) is a first-line treatment for type 2 diabetes, stimulating insulin secretion.
• Secondary SU failure, characterized by rising blood glucose after prolonged treatment, is a clinical challenge.
• The underlying causes of secondary SU failure, including proinsulin conversion defects and insulin resistance, require further investigation.

Purpose of the Study:

• To investigate whether defects in the proinsulin converting mechanism contribute to secondary SU failure.
• To compare insulin-related molecules between healthy controls, SU responders, and secondary SU failures.
• To assess the role of proinsulin conversion dysfunction versus insulin resistance in SU treatment outcomes.

Main Methods:

• Recruitment of three groups: healthy controls (n=8), SU responders (n=38), and secondary SU failures (n=46).
• Utilized a technique to specifically measure intact proinsulin (IPI), total proinsulin (TPI), and specific insulin (SI).
• Analyzed serum concentrations of insulin-related molecules and assessed the Homa Insulin Resistant Index after a standard glucose challenge test.

Main Results:

• Specific insulin (SI) levels were lower in both patient groups compared to controls (P<0.05).
• Proinsulin to insulin ratios (TPI:SI and IPI:SI) were significantly increased in patient groups (P<0.05) but did not differ between SU responders and failures.
• Secondary SU failures exhibited higher blood glucose levels post-challenge (P<0.05) with no correlation to SI, unlike SU responders.

Conclusions:

• Type 2 diabetes is associated with impaired proinsulin conversion and reduced specific insulin response to glucose challenge.
• Dysfunction in the proinsulin conversion mechanism is unlikely to be an additional cause of secondary SU failure.
• Insulin resistance may play a more significant role in the progression of secondary SU failure.